India Pesticides Ltd
NSE:IPL
Earnings Call Analysis
Summary
Q3-2024
For Q3 FY'24, India Pesticides Limited reported a total income of INR 155 crores, a decrease from INR 222 crores in Q3 FY'23, attributable to a decline in export sales. Despite this, EBITDA increased by 19% to INR 37 crores, with margins up to 25%, and net profit grew by 23% to INR 24 crores, resulting in a PAT margin of 16%. Export revenue was INR 66 crores, up from the last quarter but still facing a challenging demand environment internationally. Domestically, revenues decreased from INR 140 crores to INR 64 crores. The company invested INR 40 crores in capital expenditures (CapEx) over the first nine months and plans an outflow of INR 50 crores for FY'23-'24. Additionally, a new subsidiary, Amona Specialities Private Limited, has been formed to drive future growth by focusing on generic molecules and optimizing distribution channels.
You don't have any saved screeners yet
Ladies and gentlemen, good day, and welcome to India Pesticides Limited Q3 FY '24 Conference Call hosted by Dolat Capital. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Nitesh Dhoot from Dolat Capital. Thank you, and over to you, sir.
Thank you, Rea. Good afternoon, everyone. On behalf of Dolat Capital, I would like to thank the management of India Pesticides Limited for giving us the opportunity to host their Q3 and 9-month FY '24 Earnings Conference Call.
From the management team, we have with us today Mr. D.K. Jain, Chief Executive Officer; and Mr. S.P. Gupta, Chief Financial Officer.
Without further ado, I would like to hand over the call to the management for their opening remarks, post which, we'll open the forum for a Q&A session. Thank you, and over to you, sir.
Thank you, Nitesh. Good afternoon, ladies and gentlemen. I hope you and your family are staying safe and healthy. I take the pleasure of welcoming you all for the Q3 FY '24 Earnings Conference Call of India Pesticides. I hope you all had the chance to look at the financial statements and earnings presentation uploaded on the exchanges and our website.
Before we dwell into today's agenda, I wish to inform you that our [ promoter ] Director, Mr. Anand Swarup Agarwal, is unable to join us on this call due to some unavoidable circumstances. He has conveyed his best wishes to you all.
Friends, during the quarter, we continued our journey of product development and customer acquisition. Despite the headwinds from incremental margins on account of destocking and adverse weather conditions, your company remains steadfast in its commitment and delivered strong performance during the quarter. Our relentless focus on operating excellence, optimizing asset use, product mix optimization and implementation of robust business controls have enabled us to navigate these challenges more effectively than before.
Our proficiency in advanced process chemistry, manufacturing efficiency and backward integration strategies have positioned our company in the forefront of the industry. These core strengths not only ensured consistent performance, but also laid the foundation for sustainable growth. We get pride in being a Made in India company and remain committed to promote domestic agrochemical production.
Moving on to strategic development during the quarter. Our expansion project through our subsidiary is progressing as planned, and we anticipate commissioning the first block by the end of this fiscal year. Our advanced herbicide technical product has been granted with technical equivalence, TEQ certification by the European Union. This recognition is a testament to the quality and efficiency -- efficacy of our products. And it is poised to unlock new opportunities for export revenue, thereby contributing significantly to our nation's foreign earnings.
During the quarter, we have strengthened our leadership team by welcoming Dr. Madhu Dikshit as chairperson. With her steady leadership and extensive experience, she will play a pivotal role in creating value for all stakeholders and reinforcing controls and governance.
Furthermore, we are excited to announce that we have entered in a 3-year contract with a prominent Japanese company to supply an intermediate. This collaboration reflects our commitment to cultivating strong partnerships and enhancing our global footprint. With our proven expertise and unwavering dedication to excellence, we are poised to deliver premium quality products, driving mutual success and fostering growth for both entities involved. We are optimistic on our long-term growth on the back of our strong fundamentals and R&D at the core, leading to renewed focus on new product development and help towards the era of growth and higher profitability.
I would like to express my gratitude for you -- for your unwavering support and confidence in our vision. Together, we will continue to drive innovation, pursue excellence and create long-term value for our shareholders. With this, I would like to pass on to Mr. S.P. Gupta to walk us through our Q3 FY '24 financial highlights. Mr. S.P. Gupta.
Thank you, sir. Good afternoon, ladies and gentlemen, and thank you for joining the India Pesticides conference call to discuss the Q3 and 9 months FY '24 results. I will quickly walk through our financial performance.
Total income for Q3 FY '24 was INR 155 crores as compared to INR 222 crores generated in Q3 FY '23 due to decline in export sales. In Q3 FY '24, we registered EBITDA of INR 37 crores, a sequential growth of 19%, with EBITDA margin up 25%. The net profit for the Q3 FY '24, it stood at INR 24 crores, a sequential growth of 23%, with PAT margin of 16%. Company's margin and profitability remained strong this quarter.
Revenue for export stood at INR 66 crores as compared to INR 62 crores achieved in last quarter, and domestic revenue stood at INR 64 crores as compared to INR 140 crores achieved in last quarter. Revenue from technicals and formulation stood at INR 124 crores and INR 29 crores, respectively.
Export continued to witness challenges during the quarter. Demand environment in international market remain challenging amidst high channel inventory and destocking by MNC. We have spent INR 40 crores on CapEx in first 9 months of the year. The CapEx outflow of INR 50 crores has been planned for FY '23, '24 by IPL.
Looking ahead, we are excited to announce the establishment of our new subsidiary, Amona Specialities Private Limited. The entity will focus on identifying generic molecules, maybe getting regulatory process for product registration and optimizing distribution channel. By doing so, we aim to accelerate our growth trajectory and capitalize on emerging market opportunities. India Pesticides Limited has a strong balance sheet with the ability to generate good free cash flow. Company is planning to fuel its CapEx plan with internal accruals.
Our cash and cash equivalent at the end of Q3 FY '24 INR 153 crores. We remain confident of continuing our growth trajectory while extending full support to our customer, supplier and valued stakeholders.
With this, we would be happy to take your questions. Thank you.
[Operator Instructions] First question is from the line of Rahul Jain from Credence Wealth.
And congratulations on a good set of numbers in a tough environment. So the first question is that you mentioned in your initial remarks and also in the press release and the presentation about the environment being continues not to be good. So typically, what is your judgment in terms of prices of products as well as raw materials in last 3, 4 months now? Have they stabilized? And are they -- started gradually moving up or no? First of all the pricing of the products and the raw materials?
The raw material prices, Rahul, they are on a very low level, and they have stabilized. The -- pricing is different in different molecule. In some products, they have stabilized even slightly higher. And in some products, they have settled on a lower level, but they have stabilized.
Sure. So that means that there is no further fall in the prices which is visible in last 2, 3 months? Is that a correct understanding?
Yes, yes.
And sir, with regards to going ahead, both on the inventory side and the demand side, what is your judgment, understanding when you speak to your customers, both domestic and some of the large MNCs? How do you view the environment change going ahead?
Sir, the international environment still looks to be slightly confusing, in the sense that the MNCs, they still have a lot of stock. They are slightly hesitant to put all their purchase orders at a time as normally they used to do. And we feel probably it may take another 1 or 2 quarters before things really get stabilized.
So we have a good gross margin improvements you have mentioned. So if you could share some more details apart from what we have mentioned in the presentation in terms of the product mix and domestic demand. But exactly how -- what kind of product mix we have changed or what exactly is driving the gross margins? And what is the sustainable gross margin going ahead?
Mr. Gupta will reply to this.
Rahul, the higher gross profit margin is due to combination of 2 factors. First, the product mix was better this quarter. Secondly, during this quarter, we got converted one of our raw material on [indiscernible] basis, which we were earlier buying. Company has paid [ jobs ] worth charges of INR 4 crores. This has resulted in higher other expenses and reduction in cross consumed. If we adjust this amount, gross profit would be around 50%. So in future, also because of our stabilization of new products, we think gross profit margin will be, say, in this range only 48% to 52%.
Okay. Last question, sir. We are planning to complete about INR 110 crores of CapEx by FY -- by March '24, right? We have done about INR 60 crores and further about INR 40 crores to be spent by March?
Yes, yes.
So given the prices where we stand today, how do you look at the top line for the next year, FY '25 and FY '26?
The top line for FY '25, '26, we feel it should increase about 15% to 20% over this year because what has happened overall, there has been a decline in the product finished good prices. So it will impact the revenue. But this year itself, our revenue slightly lower than last year. So over this, we expect around 15% to 20% increase.
That is for FY '25?
Yes, sir.
And given the CapEx completed, what could -- by March '24 and the ramp-up happening, that ramp up to take another 6 to 9 months for the ramp-up to be applied fully?
Rahul, could you please repeat? We could not understand.
You mentioned about 15%, 20% growth at today's prices for top line for FY '25. But given the CapEx which we are doing, so how will we look at FY '26? And the ramp-up of the new CapEx?
Yes. So FY '26 also sir, we will continue to grow at almost 20%.
[Operator Instructions] Next question is from the line of [ M.N. Kumar ], an individual investor.
Sir, this time -- can you give some projections with respect to what happened on the volume side, sir?
The volume for this quarter, it has declined by 30% as compared to Q3 FY '23.
Okay. So that means the pricing wise, the December 2022 versus December 2023. Prices are the same, and all this decline is predominantly because of the price -- volume only. Is that my understanding right, sir?
Yes, yes. Price on blended basis remain same. On some products, there was a slight increase and some has declined. So the reduction in turnover is because of volume only.
Okay. So how do you see the volume production for Q4, sir?
Q4 volume, we expect they will rise, but it is very difficult to see volume growth as compared to last -- fourth quarter of last year. But definitely, it will increase from this quarter.
And how are your exports doing, sir? We understand that Chinese are having a lot of capacities on this one. Any of the molecules we are working, either China is adding volumes, do you hear anything like that?
China, they are putting up very large plants for some of the very popular products. So for our expansion projects, we are reconsidering those particular products. But presently, the products in which we are operating, China is not very aggressive. Only major problem what we are facing is that our MNC customers, they have slowed down their purchase, considering the high inventory cost, they don't want to carry it. That is why they have slightly curtailed, and we expect that this will increase and become normalize maybe by next quarter.
And how do you see the domestic market formulation business? Are you planning to expand that because many of the people in agrochem business, India focused business seems to be in a better position than compared to exports. What is -- any thoughts on that, sir?
No, that is true. Relatively, the position in India is better than the international market. And our formulation business is going on smoothly and it is slightly on increased path. So we are going to increase the formulation business during the -- this season, the coming season.
The first block that you are establishing, which is going to be into production in the Q4, how is that coming up? And what kind of products you would be making there? Would that be for export or domestic market, sir?
The first block we have put up there, there are 2 blocks under construction. One is for the formulated -- formulations, another block is for Intermediate. And we want to commission the formulation plant for us as we have got some orders in hand for our domestic as well as for some export market. And another 2 to 3 months, we will be starting the Intermediate project plant.
[Operator Instructions]
If there are no questions, we can stop.
As there are no further questions, I would now like to hand the conference over to Mr. Akanksha Singh from Dolat Capital for closing comments.
And with that, we'll come to the end of the Q&A session. Thanks a lot to the management of India Pesticides Limited for answering every question in detail. Thanks, again, everyone, for their participation, and have a great day ahead. I now hand over the call to the management for the closing remarks. Thank you.
Thank you very much. Thank you, everyone, for their participation. For any further questions or queries, please do get in touch with our Investor Relations team. Thank you. Have a nice day.
Thank you. On behalf of Dolat Capital, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.